Investment & Exit Overview
CrossBridge Bio has been acquired by Eli Lilly and Company for $300 million, representing a significant exit for the Texas Medical Center Venture Fund.
The company was founded in 2023 through the TMC Innovation Accelerator for Cancer Therapeutics, with the venture fund serving as lead and initial investor.
The startup was built by connecting:
• Dr. Michael Torres (CEO), recruited through the Entrepreneur in Residence program
• Dr. Kyoji Tsuchikama, academic co-inventor
• Dr. Zhiqiang An, contributing scientific founder
This combination of academic science and experienced biotech leadership enabled rapid progression from platform development to acquisition.
Strategic Relevance for GAP Leaders
This case represents a complete GAP-to-exit pipeline model, demonstrating:
• Accelerator-led company formation grounded in academic IP
• Institutional venture capital as first check providing early conviction
• Entrepreneur-in-Residence model to match talent with technology
• Clinical ecosystem integration supporting validation and strategy
• Rapid pathway to strategic acquisition by a global pharma company
The model reinforces that successful commercialization requires alignment of:
• capital
• talent
• translational infrastructure
• industry connectivity
For GAP programs, this is a blueprint for building venture-backable companies with clear exit pathways.
Innovation & Technology
CrossBridge Bio is developing next-generation antibody-drug conjugates (ADCs) featuring dual payload technology, designed to improve cancer treatment precision and effectiveness.
The platform includes:
• Proprietary linker technology enabling greater stability
• Ability to attach multiple therapeutic payloads
• Targeting mechanisms addressing tumor heterogeneity and resistance
Lead program:
• CBB-120, a TROP2-targeting ADC for breast and other solid tumors
The technology originates from research at UTHealth Houston and represents an evolution of ADC design toward more effective oncology therapies.
Potential Market Applications
CrossBridge Bio – Dual-Payload Antibody-Drug Conjugates
CEO: Dr. Michael Torres
Scientific Founders: Dr. Kyoji Tsuchikama, Dr. Zhiqiang An
Ecosystem: Texas Medical Center / TMC Innovation
Market Applications
• Targeted oncology therapeutics: Dual-payload ADCs improving treatment precision for breast cancer and other solid tumors.
• Next-generation drug delivery platforms: Technologies addressing tumor resistance and heterogeneity in cancer treatment.
• Pharmaceutical pipeline expansion: Platform-based ADC development for multiple cancer indications across biotech and pharma pipelines.
Read the Full Story:
https://www.tmc.edu/press-releases/texas-medical-center-venture-fund-announces-acquisition-of-crossbridge-bio-for-300-million-by-eli-lilly/
Related Topics:
biotech commercialization, antibody-drug conjugates, university venture funds, accelerator-to-exit pathways, oncology innovation, translational medicine
